Qianjiang Yongan Pharmaceutical Co., Ltd. (SHE:002365)

Market Cap	3.54B +23.4%
Revenue (ttm)	847.91M +4.3%
Net Income	34.60M +20.5%
EPS	0.12 +22.1%
Shares Out	289.15M
PE Ratio	102.35
Forward PE	n/a
Dividend	0.10 (0.80%)
Ex-Dividend Date	Jul 9, 2025

Volume	7,019,100
Average Volume	7,407,344
Open	13.06
Previous Close	12.57
Day's Range	12.24 - 13.06
52-Week Range	12.24 - 32.14
Beta	0.52
RSI	34.75
Earnings Date	Aug 28, 2026

About SHE:002365

Qianjiang Yongan Pharmaceutical Co., Ltd. engages in production and sale of taurine in China. It produces ethylene oxide, polycarboxylic acid-based water reducer monomers, water reducers, and health products. The company engages in scientific research and technical service, creatine monohydrate, wholesale and retail trade, leasing and business services, and crop farming. Qianjiang Yongan Pharmaceutical Co., Ltd. was founded in 2001 and is based in Qianjiang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 912
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002365

Financial Performance

In 2025, SHE:002365's revenue was 783.17 million, a decrease of -6.63% compared to the previous year's 838.81 million. Earnings were 22.49 million, a decrease of -63.58%.